Skip to main content
Neda Rasouli, MD, Endocrinology, Aurora, CO

NedaRasouliMD

Endocrinology Aurora, CO

Diabetes, Lipid Metabolism

Associate Professor, Medicine, University of Colorado School of Medicine

Dr. Rasouli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rasouli's full profile

Already have an account?

  • Office

    12605 E 16th Ave
    Aurora, CO 80045
    Phone+1 720-848-0000

Education & Training

  • University of Arkansas for Medical Sciences (UAMS) College of Medicine
    University of Arkansas for Medical Sciences (UAMS) College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2000 - 2002
  • Sparrow Hospital/Michigan State University
    Sparrow Hospital/Michigan State UniversityResidency, Internal Medicine, 1997 - 2000
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 1995

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2009 - 2025
  • AR State Medical License
    AR State Medical License 2000 - 2010
  • MI State Medical License
    MI State Medical License 2000 - 2001
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Most Compassionate Doctor American Registry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Glycaemic Efficacy and Safety of Linagliptin Compared to Basal‐Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non‐Cardiac Surgery: A Multicenter Ran...  
    Neda Rasouli, MD, Diabetes, Obesity and Metabolism

Press Mentions

  • Given Shortages, Who ‘Deserves’ Ozempic and GLP-1 Drugs?
    Given Shortages, Who ‘Deserves’ Ozempic and GLP-1 Drugs?August 10th, 2024
  • Research Helps Show Which Type 2 Diabetes Medication May Work Best
    Research Helps Show Which Type 2 Diabetes Medication May Work BestJuly 23rd, 2024
  • Should Metformin Remain the First-Line Therapy for Treatment of Type 2 Diabetes?
    Should Metformin Remain the First-Line Therapy for Treatment of Type 2 Diabetes?January 13th, 2021
  • Join now to see all

Grant Support

  • Effects Of Insulin Sensitizers And PPAR Ligands On Lipotoxicity In Subjects WithNational Center For Research Resources2006
  • Effects Of Insulin Sensitizers On Glucose And Fat Metabolism In Subjects With GENational Center For Research Resources2005–2006
  • Effects Of Insulin Sensitizers Of Beta Cell Function And LipotoxicityNational Center For Research Resources2005–2006
  • Pathophysiology Of Atypical Diabetes In African Americans: A Pilot ProposalNational Center For Research Resources2004
  • Insulin Sensitizers Of Beta Cell Function &LipotoxicityNational Center For Research Resources2004

Committees

  • member, Standards of Medical Care in Diabetes - 2015